Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Directly disrupting the Hsp90-Cdc37 complex can selectively down-regulate kinase clients of Hsp90 and achieve cell cycle arrest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, the heat shock protein (Hsp90)-Cdc37 PPI promotes colorectal cancer.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [104]
In the citing paper
“PPI inhibitors of Hsp90-Cdc37 could achieve selective inhibition of Hsp90 kinase without affecting other interactions that could lead to unnecessary toxicity [104].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., et al. (2000) · Accounts of Chemical Research · doi:10.1021/ar000033j · Cited by 4,978
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Gohlke, H., Kiel, C., & Case, D. A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00610-7 · Cited by 1,192 · cited 1×
“(35, 36), which might provide critical insights into hotspots.”
BackgroundHsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K. D., Karras, G. I., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.047 · Cited by 879 · cited 1×
“Quantitative analysis of Hsp90-cochaperone interactions has been reported to reveal specificity in substrate recognition (6).”
BackgroundConverging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf
Gohlke, H., & Case, D. A. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.10379 · Cited by 860 · cited 1×
“(35, 36), which might provide critical insights into hotspots.”
BackgroundCheatham, T. E. I., Miller, J. L., Fox, T., Darden, T. A., & Kollman, P. A. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00119a045 · Cited by 859 · cited 1×
“In the whole simulation process, the particle mesh Ewald method was used to calculate long-range electrostatic interactions (33).”
MethodAll-Atom Structure Prediction and Folding Simulations of a Stable Protein
Simmerling, C., Strockbine, B., & Roitberg, A. E. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0273851 · Cited by 589
Cited by
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions
Li, L., Wang, L., You, Q.-D., & Xu, X.-L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00940 · Cited by 202
Self-citationRational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions
Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 150
“Without doubt, it is an ever challenging task to design small molecules possessing rigid and hydrophobic features by downsizing the molecular size and mimicking key residues of original peptides (Wang et al., 2019).”
BackgroundPAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson’s disease
Park, H., Kam, T., Peng, H., Chou, S.-C., Mehrabani-Tabari, A. A., Song, J., Yin, X., Karuppagounder, S. S., Umanah, G. K. E., Rao, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.020 · Cited by 134
Heat shock protein 90: biological functions, diseases, and therapeutic targets
Wei, H., Zhang, Y., Jia, Y., Chen, X., Niu, T., Chatterjee, A., He, P., & Hou, G. (2024) · MedComm · doi:10.1002/mco2.470 · Cited by 131
“159 Furthermore, Chen et al. 273 conducted a study on another inhibitor known as DCZ3112, which also targets the HSP90–CDC37 PPI.”
BackgroundZuo, W., Pang, Q., Zhu, X., Yang, Q., Zhao, Q., He, G., Han, B., & Huang, W. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01601-1 · Cited by 113
Serwetnyk, M. A., & Blagg, B. S. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.015 · Cited by 103
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“PPI inhibitors of Hsp90-Cdc37 could achieve selective inhibition of Hsp90 kinase without affecting other interactions that could lead to unnecessary toxicity [104].”
BackgroundCheng, K., Liu, B., Zhang, X., Zhang, R., Zhang, F., Ashraf, G., Fan, G., Tian, M., Sun, X., Yuan, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32349-2 · Cited by 91
Advances in the structures, mechanisms and targeting of molecular chaperones
Gu, J., He, Y., He, C., Zhang, Q., Huang, Q., Bai, S., Wang, R., You, Q., & Wang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02166-2 · Cited by 84
Self-citationTargeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancer
Wang, L., Zhang, Q., & You, Q. (2021) · Medicinal Research Reviews · doi:10.1002/med.21807 · Cited by 83
“Together, this evidence proved that pharmacologically blocking the HSP90–CDC37 PPI could selectively inhibit the HSP90 kinase client maturation to exert potential antiproliferative effects, making the HSP90–CDC37–kinase chaperone cycle a valuable target for the design of reasonable therapeutics.(57) In this review, we…”
BackgroundSelf-citationTargeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects
Liang, X., Chen, R., Wang, C., Wang, Y., & Zhang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00966 · Cited by 51
Self-citationEmerging prospects of extracellular vesicles for brain disease theranostics
Wang, R., Wang, X., Zhang, Y., Zhao, H., Cui, J., Li, J., & Di, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.024 · Cited by 48
The chaperone system in cancer therapies: Hsp90
Basset, C. A., de Macario, E. C., Leone, L. G., Macario, A. J. L., & Leone, A. (2023) · Journal of Molecular Histology · doi:10.1007/s10735-023-10119-8 · Cited by 45
“This could be explained by the pan-inhibitory effect of the semi-synthetic and fully synthetic compounds that trigger the HSR and increase Hsp70 expression as a pro-survival response, which brings the need of higher doses to maintain the inhibitory effect, but this is paralleled by an increase in toxicity (Wang et al.…”
BackgroundInfluentialChen, W., Chen, X., Li, D., Zhou, J., Jiang, Z., You, Q., & Guo, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00091 · Cited by 45
Self-citationWang, L., Jiang, J., Zhang, L., Zhang, Q., Zhou, J., Li, L., Xu, X., & You, Q. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01659 · Cited by 37
Self-citationWang, J., Cao, D., Tang, C., Xu, L., He, Q., Yang, B., Chen, X., Sun, H., & Hou, T. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa183 · Cited by 44
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs)
Qiu, Y., Li, X., He, X., Pu, J., Zhang, J., & Lu, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112764 · Cited by 45
Self-citationAn updated patent review of anticancer Hsp90 inhibitors (2013-present)
Li, L., Chen, N., You, Q., & Xu, X. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1829595 · Cited by 44
Self-citationBanerjee, M., Hatial, I., Keegan, B. M., & Blagg, B. S. J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107747 · Cited by 43
“Docking studies have also been used to identify small molecule disruptors Hsp90-Cdc37 interactions (Wang et al., 2019).”
BackgroundMethodInfluentialModulation of protein fate decision by small molecules: targeting molecular chaperone machinery
Wang, L., Xu, X., Jiang, Z., & You, Q. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.018 · Cited by 40
Self-citationTomašič, T., Durcik, M., Keegan, B. M., Skledar, D. G., Zajec, Ž., Blagg, B. S. J., & Bryant, S. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186898 · Cited by 39
“Consequently, alternative mechanisms, such as selective Hsp90β inhibition [12], allosteric Hsp90 CTD inhibition [13], covalent Hsp90 inhibition [14], and/or targeting protein-protein interactions between Hsp90 and its co-chaperones [15], are promising new approaches being pursued [16].”
BackgroundXu, H., Gan, C., Xiang, Z., Xiang, T., Li, J., Huang, X., Qin, X., Liu, T., Sheng, J., & Wang, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114575 · Cited by 37
Camps-Fajol, C., Cavero, D., Minguillón, J., & Surrallés, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107544 · Cited by 36
Yin, L., Yang, Y., Zhu, W., Xian, Y., Han, Z., Huang, H., Peng, L., Zhang, K., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620907 · Cited by 36
Liu, X., Liu, M., Jiang, L., Gao, L., Zhang, Y., Huang, Y., Wang, X., Zhu, W., Zeng, H.-X., Meng, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108849 · Cited by 36
Prodrug-inspired adenosine triphosphate–activatable celastrol-Fe(III) chelate for cancer therapy
Li, H., Li, Y., Zhang, L., Wang, N., Lu, D., Tang, D., Lv, Y., Zhang, J., Yan, H., Gong, H., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn0960 · Cited by 33
Self-citationApplications of Solution NMR in Drug Discovery
Li, S., & Zhang, N. (2021) · Molecules · doi:10.3390/molecules26030576 · Cited by 31
“PPI modulators, which present increased target or signal pathway selectivity and decreased off-target side effects, have high potentials for therapeutic uses [30].”
BackgroundZhao, C., Le, X., Li, M., Hu, Y., Li, X., Chen, Z., Hu, G., Hu, L., & Li, Q. (2023) · Respiratory Research · doi:10.1186/s12931-023-02600-5 · Cited by 30
“Of note, disrupting the protein-protein interaction (PPI) between HSPs and their clients is emerging as a promising strategy for cancer therapy, which allows for targeting the non-conserved regions of the protein [27, 28].”
BackgroundDiscovery of Novel Celastrol–Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo
Li, N., Xu, M., Zhang, L., Lei, Z., Chen, C., Zhang, T., Chen, L., & Sun, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01293 · Cited by 28
Self-citationCheng, C., Liu, K., Zhang, M., Shen, F.-K., Ye, L.-L., Wu, W., Hou, X., Hao, E., Hou, Y., & Bai, G. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00737-x · Cited by 25
Wang, X., Liu, Q., Wu, S., Xu, N., Li, H., & Feng, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.739478 · Cited by 25
“In ovarian cancer, FN1 induces invasion and migration by upregulating the PI3K/Akt pathway (Wang et al., 2019).”
BackgroundSmall molecule inhibitors targeting heat shock protein 90: An updated review
Li, Y., Dong, J., & Qin, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116562 · Cited by 25
Wang, L., Bergkvist, L., Kumar, R., Winblad, B. G., & Pavlov, P. F. (2021) · Cells · doi:10.3390/cells10102596 · Cited by 25
“identified polar interactions between Arg167 on Cdc37 and Glu47 and Gln133 on Hsp90 as the most important binding determinants in recognition during the dynamic cycle of the Hsp90–Cdc37 interaction [99].”
BackgroundSelf-citationWang, L., Shen, Q., Liao, H., Fu, H., Wang, Q., Yu, J., Zhang, W. Y., Chen, C., Dong, Y., Yang, X., et al. (2021) · Advanced Science · doi:10.1002/advs.202003558 · Cited by 24
Self-citationNovel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling
Siddiqui, F. A., Parkkola, H., Vukić, V., Oetken-Lindholm, C., Jaiswal, A., Kiriazis, A., Pavic, K., Aittokallio, T. A., Salminen, T. A., & Abankwa, D. (2021) · Cancers · doi:10.3390/cancers13040927 · Cited by 23
“While the computational and experimental structural data from us and others identified novel small molecule inhibitors binding to a Hsp90 surface in the vicinity of the ATP-binding pocket, they did not disrupt ATP-pocket binding [26].”
BackgroundResultInfluentialBai, H., Lyu, J., Nie, X., Kuang, H., Liang, L., Jia, H., Zhou, S., Li, C., & Li, T. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.06.004 · Cited by 23
“It is known that E47A and Q133A have completely lost bindingcapabilitywithCDC37,whileY61Ahassigni fi cantlydecreased binding af fi nity [29].”
BackgroundMethodInfluentialWu, X., Zhang, Q., Guo, Y., Zhang, H., Guo, X., You, Q., & Wang, L. (2022) · Antioxidants · doi:10.3390/antiox11040619 · Cited by 22
“The docking results obtained by treating ligands and receptors as flexible structures are relatively more accurate [107].”
BackgroundSelf-citationZhang, Q., Wu, X., Zhou, J., Zhang, L., Xu, X., Zhang, L., You, Q., & Wang, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112959 · Cited by 22
Self-citationLi, L., Chen, N., Xia, D., Xu, S., Dai, W., Tong, Y., Wang, L., Jiang, Z., You, Q., & Xu, X. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.016 · Cited by 22
Self-citationLu, D., Liu, R., Zhou, Y., Zhang, Z., Jiang, X., Xu, J., Su, A., & Hu, Z. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110500 · Cited by 22
Exploring the landscape of post-translational modification in drug discovery
Cao, Y., Yu, T., Zhu, Z., Zhang, Y., Sun, S., Li, N., Gu, C., & Yang, Y. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108749 · Cited by 21
Crizotinib: A Novel Strategy to Reverse Immunosuppression in Melanoma by Targeting Lactate Transport
Zhou, Z., Zhang, X., Zhu, S., Liu, W., Guo, Y., Xiong, S., Peng, C., & Chen, X. (2025) · MedComm · doi:10.1002/mco2.70286 · Cited by 195
Pan, Z., Chen, Y., Pang, H., Wang, X., Zhang, Y., Xie, X., & He, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114674 · Cited by 20
Interface-aware molecular generative framework for protein–protein interaction modulators
Wang, J., Mao, J., Li, C., Xiang, H., Wang, X., Wang, S., Wang, Z., Chen, Y., Li, Y., No, K. T., et al. (2024) · Journal of Cheminformatics · doi:10.1186/s13321-024-00930-0 · Cited by 19
Qin, F., Xia, W., Wang, S., Dai, G., Jiao, W., Guo, N., Li, H., & Zhang, G. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00052-1 · Cited by 18
“It is well known that Hsp27, Hsp70, Hsp90 and other chaperone proteins are often enhanced in the process of tumorigenesis, and play an important role in many key steps of tumorigenesis and development [92, 93].”
BackgroundInfluentialDike, P. P., Bhowmick, S., Eldesoky, G. E., Wabaidur, S. M., Patil, P. C., & Islam, M. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1835714 · Cited by 17
Elaiophylin Is a Potent Hsp90/ Cdc37 Protein Interface Inhibitor with K-Ras Nanocluster Selectivity
Siddiqui, F. A., Vukić, V., Salminen, T. A., & Abankwa, D. (2021) · Biomolecules · doi:10.3390/biom11060836 · Cited by 17
“5 μM) Hsp90/ Cdc37 interface inhibitors with anti-tumor activities in vivo [24,25].”
BackgroundCdc37 as a Co-chaperone to Hsp90
Prince, T. L., Lang, B. J., Okusha, Y., Eguchi, T., & Calderwood, S. K. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-14740-1_5 · Cited by 17
Therapy resistance: Modulating evolutionarily conserved heat shock protein machinery in cancer
Skrabalak, I., Rajtak, A., Małachowska, B., Skrzypczak, N., Skalina, K. A., Guha, C., Kotarski, J., & Okła, K. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217571 · Cited by 15
Allosteric CDC37 Inhibitor Disrupts Chaperone Complex to Block CDK4/6 Maturation
Zhang, L., Liu, W., Zheng, Z., Zhang, Q., He, Y., Gu, J., Wang, D., Shu, H., Yu, J., Liu, J., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202413618 · Cited by 15
Self-citationHu, L.-P., Zhou, K., Huo, Y., Liu, D., Li, Q., Yang, M., Huang, P.-Q., Xu, C., Tian, G.-A., Yao, L., et al. (2021) · Oncogenesis · doi:10.1038/s41389-021-00311-4 · Cited by 15
Small molecules targeting molecular chaperones for tau regulation: Achievements and challenges
He, C., Gu, J., Wang, D., Wang, K., Wang, Y., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115859 · Cited by 14
Self-citationVeale, C. G. L., Mateos‐Jimenez, M., Vaaltyn, M. C., Müller, R., Makhubu, M., Alhassan, M., de la Torre, B. G., Alberício, F., Mackay, C. L., Edkins, A. L., et al. (2021) · Chemical Communications · doi:10.1039/d1cc04257b · Cited by 14
Zamer, B. A., El‐Huneidi, W., Eladl, M. A., & Muhammad, J. S. (2021) · Cells · doi:10.3390/cells10112862 · Cited by 15
“One of these compounds is the small-molecule inhibitor DDO-5936 [80].”
BackgroundDisrupting the Hsp90–Cdc37 axis: a selective strategy for targeting oncogenic kinases in cancer
Kamel, E. M., Ali, M. A. M., Allam, A. A., Ahmed, N., Alkhayl, F. F. A., & Lamsabhi, A. M. (2025) · RSC Advances · doi:10.1039/d5ra03137k · Cited by 12
Wang, X., Ni, R., Wang, X., & Li, X. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02559-5 · Cited by 12
“Beyond direct inhibition of HSP90’s functional domains, an emerging strategy focuses on disrupting critical protein-protein interactions (PPIs) within the chaperone machinery, particularly the interface between HSP90 and its co-chaperones [63].”
Bezawy, R. E., Percio, S., Ciniselli, C. M., Cesare, M. D., Colella, G., Dugo, M., Veneroni, S., Doldi, V., Martini, S., Baratti, D., et al. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00460-7 · Cited by 12
“Such blockage has been previously described to suppress multiple pathways and to induce growth inhibition in human cancer cells [40, 41].”
BackgroundZhao, C., Wu, Y., Li, M., Tan, W., Hu, Y., Wang, Y., Gao, R., Hu, L., & Li, Q. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116855 · Cited by 11
Xu, L., Xu, N., Wang, L., Qian, H., Li, Y., Fang, M., Xiang, Z., Lin, W., Zhang, F., Shao, Q., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.06.025 · Cited by 11
Self-citationImpact of Co-chaperones and Posttranslational Modifications Toward Hsp90 Drug Sensitivity
Backe, S. J., Woodford, M. R., Ahanin, E. F., Sager, R., Bourboulia, D., & Mollapour, M. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-14740-1_11 · Cited by 11
Wang, R., Zhang, Y., Meng, X., Zhao, J., Xing, Y., Ouyang, Q., Zhang, N., Chen, H., Miao, N., Song, E., et al. (2025) · Advanced Science · doi:10.1002/advs.202506518 · Cited by 10
Inflammation accelerates BCR-ABL1+ B-ALL development through upregulation of AID
Zhang, P., Qin, M., Wang, Y., Chen, X., Miao, Y., Yuan, M., Zhou, W., Li, D., Wang, D., Wang, M., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005017 · Cited by 9
“Treatment with Hsp90 inhibitors effectively alleviates the effects of AID on CSR, SHM, and cell proliferation in many cancers.(37,38) The Hsp90 N-terminal inhibitor, geldanamycin, inhibits Hsp90 function through competing with ATP to bind to the Hsp90 N-terminal domain.”
BackgroundSu, G., Su, L., Luo, D., Yang, X., Liu, Z., Lin, Q., An, T., Weng, C., Chen, W., Zeng, Z., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137070 · Cited by 8
Self-citationTong, G., Cheng, B., Wu, X., He, L., Lv, G., & Wang, S. (2022) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2022042925 · Cited by 8
Dernovšek, J., Gradišek, N., Zajec, Ž., Urbančič, D., Cingl, J., Goričan, T., Grdadolnik, S. G., & Tomašič, T. (2024) · RSC Advances · doi:10.1039/d4ra05878j · Cited by 8
“45 Wang and colleagues found that the binding of DDO-5936 is largely dependent on Asp47 on the NTD of Hsp90.”
BackgroundMethodInfluentialDu, J., Liu, L., Liu, B., Yang, J., Hou, X., Yu, J., & Fang, H. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0114 · Cited by 8
Basset, C. A., Rappa, F., Barone, R., Florena, A. M., Porcasi, R., de Macario, E. C., Macario, A. J. L., & Leone, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169317 · Cited by 8
“Hsp90 has been extensively studied in relation to carcinogenesis because of various reasons, one of which is the nature of its clients, which are kinases involved in proliferative pathways activated in malignancies [27,28].”
BackgroundAllosteric Activation of Protein Phosphatase 5 with Small Molecules
Zhang, Q., Yan, L., Zhang, L., Yu, J., han, Z., Liu, H., Gu, J., Wang, K., Wang, J., Chen, F., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00722 · Cited by 7
Self-citationNatural triterpenoid-aided identification of the druggable interface of HMGB1 occupied by TLR4
Shen, P., Jiang, X., Kuang, Y., Wang, W., Raj, R., Wang, W., Zhu, Y., Zhang, X., Yu, B., & Zhang, J. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00062e · Cited by 6
Self-citationRational Design of Peptide Inhibitors Targeting HSP90–CDC37 Protein–Protein Interaction
Zhang, Q., Yan, L., Zhang, Y., Zhang, L., Yu, J., You, Q., & Wang, L. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0320 · Cited by 6
Self-citationTumour Cell Size Control and Its Impact on Tumour Cell Function
Zhou, M., Zhou, M. L., & Jin, Y. (2025) · Cell Proliferation · doi:10.1111/cpr.70080 · Cited by 6
“The small molecule inhibitor DDO-5936 inhibits the protein interaction between Hsp90 and Cdc37, suppressing colorectal cancer cell cycle progression [209].”
Fedorov, V., Kurkin, A., Fofanov, G., Kaneva, V., Kondratenko, A., Combs, S. E., & Shevtsov, M. A. (2025) · Cells · doi:10.3390/cells14231837 · Cited by 5
“As shown, the inhibition of any participant in this chaperone complex leads to the disruption of the synthesis and maturation of key kinase signaling pathways [104].”
Matlhodi, T., Makatsela, L. P., Gumede, N. J., & Mokoena, F. (2025) · Transactions of the Royal Society of South Africa · doi:10.1080/0035919x.2025.2461304 · Cited by 5
Varabyeva, N. A., Scherbakov, A. M., Salnikova, D. I., Sorokin, D. V., Khamidullina, A. I., Mikhaylova, A. L., Paulovich, D. I., Лахвич, Ф. А., & Piven, Y. A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00904e · Cited by 4
Heat shock protein 110: A novel candidate for disease diagnosis and targeted therapy
Zhao, C., Xiang, H., Li, M., Gao, R., Zhang, Y., Li, Q., & Hu, L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104199 · Cited by 4
Dual-Site Targeting by Peptide Inhibitors of the N-Terminal Domain of Hsp90: Mechanism and Design
Zang, M., Gan, H., Zhou, X., Wang, L., & Dong, H. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00629 · Cited by 4
Self-citationStructural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity
Feng, Z., Li, L., Zhang, S.-D., Ying-ji, W., Pei, J.-Y., Chen, N., Wu, B.-D., Zheng, Q., You, Q., Guo, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02182 · Cited by 4
Self-citationZhang, L., Sun, J., Wang, J., Wang, Y., Ju, W., Zhang, Y., Li, N., & Chen, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117827 · Cited by 4
Self-citationVennila, K. N., & Elango, K. P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2252080 · Cited by 4
“Rational design (X. Wang et al., 2021), fragment-based (Abell et al., 2013), hotspot-based pharmacophores (Cukuroglu et al., 2014; Guo et al., 2014; L. Wang et al., 2019), virtual screening (Sarvagalla et al., 2016) and deep learning models are a few currently used methods to probe the PPI region…”
Preclinical Evaluation of HSP90 Noninvasive Imaging in Colorectal Cancer Diagnosis
Zou, L., Chang, Q., Chen, C., Li, A., Luo, Y., Wang, X., Li, X., Wu, Z., Zhou, M., Xu, H., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c05864 · Cited by 3
Targeting Cell division cycle 37: A Promising Novel Therapeutic Strategy
Zhang, L., Xin, Y., You, Q., & Wang, L. (2025) · ChemMedChem · doi:10.1002/cmdc.202500794 · Cited by 3
Self-citationThe Chaperone Hsp90, a Key Player in Salivary Gland Tumorigenesis
Basset, C. A., Hussein, I. H., Jurjus, A. R., Cappello, F., de Macario, E. C., Macario, A. J. L., & Leone, A. (2023) · Applied Biosciences · doi:10.3390/applbiosci2040038 · Cited by 3
Alphappimi: a comprehensive deep learning framework for predicting PPI-modulator interactions
Liu, D., Song, T., Wang, S., Li, X., Han, P., Wang, J., & Wang, S. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01077-2 · Cited by 2
“To demonstrate the practical predictive capability of Alp-haPPIMI, we conducted an in-depth case study focusing on the PPI between Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 (Cdc37) [50].”
Yu, A., Banerjee, S., Malasani, S., Towolawi, B. T., Liu, Z., & Wang, Z. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111018 · Cited by 2
“Although the HSP90 and CDC37 interface is vast and dynamic (7), the α C helix– β 4 loop is a well-defined structural motif conserved across RAF and other kinases (29).”
Computational Structural Modeling to Discover PPI Modulators
Yang, X., & Ivanov, A. A. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016544-00087 · Cited by 2
Molecular simulation studies on a zwitterionic peptide-dendrimer conjugate for integrin αvβ3 binding
Lin, X., Xu, N., Li, C., Wu, Z., Chen, S., Shi, Y., & He, Y. (2023) · Biointerphases · doi:10.1116/6.0002713 · Cited by 2
Genetic variants in HSP40 co-chaperones modulate ischemic heart disease risk
Полшведкина, О. Б., Kobzeva, K., & Bushueva, O. Y. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11014-z · Cited by 1
“Although heat shock proteins have been previously implicated in CVD pathology [8, 10], and their inhibition is considered a promising therapeutic strategy [32, 33], the role of the HSP40 (DNAJ) co-chaperones remains under-explored.”
Overview of Drug Discovery Targeting PPI Systems
Ma, H., & Zhang, J. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch2 · Cited by 1
Self-citationSingh, S., Saini, V., Shevtsov, M., & Jha, H. C. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.11.005 · Cited by 1
Fianco, G., Taddei, I., Oropallo, V., Contadini, C., Ferri, A., Coculo, L., Serapian, S. A., Colombo, G., Stagni, V., & Barilà, D. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120110 · Cited by 1
Chaperones in kinase homeostasis and drug discovery
Wen, C., You, Q., & Wang, L. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.06.004 · Cited by 1
Self-citationLiu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
“A related strategy is embodied by the small molecule DDO-5936 (Wang et al., 2019), which targets the key residue Glu47 on the HSP90 cochaperone to specifically disrupt HSP90-CDC37 interaction and selectively downregulate steady-state levels of a range of oncogenic kinases.”
Allosteric CDC37 Inhibitor Disrupts Chaperone Complex to Block CDK4/6 Maturation
Zhang, L., Liu, W., Zheng, Z., Zhang, Q., He, Y., Gu, J., Wang, D., Shu, H., Yu, J., Liu, J., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202413618 · Cited by 1
Self-citationNačrtovanje in sinteza zaviralcev stresnega proteina Hsp90 z različnimi mehanizmi delovanja
Gradišek, N. (2023) · Repository of the University of Ljubljana (University of Ljubljana) · Cited by 1
Complex structure of human Hsp90N and a novel small inhibitor FS5
Liu, R., Lu, X.-L., Huang, X., He, W., Duan, J., Zhang, J., & Li, J. (2020) · Nuclear Science and Techniques · doi:10.1007/s41365-020-0739-3
Self-citationD1.1 Report on protein stability and folding
Gala, M., Džupponová, V., & Žoldák, G. (2022) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.6403225
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics
Zhao, R., Zhao, C., Gao, R., Cai, Q., Li, Q., & Hu, L. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104287
Zhao, C., Le, X., Li, M., Hu, Y., Li, X., Chen, Z., Hu, G., Hu, L., & Li, Q. (2023) · Figshare · doi:10.6084/m9.figshare.24585883
Sinteza pirimidinskih zaviralcev interakcije med stresnim proteinom Hsp90 in košaperonom Cdc37
Gaberc, T. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Lin, H., Bao, Y., Cheng, X., Zhang, S., Zhou, D., & Que, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1687690
Metadata
- Authors
- Wang, L., Zhang, L., Li, L., Jiang, J., Zheng, Z., Shang, J., Wang, C., Chen, W., Bao, Q., Xu, X., Jiang, Z., Zhang, J., & You, Q.
- Affiliations
- China Pharmaceutical University (CN)
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Jiang, Zhengyu
- Zhang, Jian
- You, Qidong
- ORCID
- Venue
- Science Advances
- Published
- 2019-09-06
- Volume
- 5
- Issue
- 9
- Pages
- eaax2277-eaax2277
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC6750927
- OpenAlex
- W2974325953
- Cited by
- 110
- References
- 39
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 18 · 2023: 10 · 2022: 17 · 2021: 16 · 2020: 14 · 2019: 1
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81573346, 81773639, 81773581, 81602948)
- China Postdoctoral Science Foundation (2018M642376)
- Double First Class Innovation Team of China Pharmaceutical University (CPU2018GY02)
- Natural Science Foundation of Jiangsu Province of China (BK2016746)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- protein-protein interaction, small molecule inhibitors, colorectal cancer, CDK4, cell cycle arrest, HCT116 cells, Hsp90 chaperone, cancer therapy
- MeSH terms
- A549 Cells, PC-3 Cells, Animals, Antineoplastic Agents, Humans, Mice, Inbred BALB C, Mice, Nude, Neoplasm Proteins, Colorectal Neoplasms, Cell Cycle Proteins, Chaperonins, HSP90 Heat-Shock Proteins, HT29 Cells, Xenograft Model Antitumor Assays, HCT116 Cells, Mice, Hep G2 Cells, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.